Compare Hilton Hotels Corporation Common Stock (HLT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs BIO-TECHNE Corp — how do they compare? Hilton Hotels Corporation Common Stock trades at $323.19 (market cap $72.14B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 6.3× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals — on Pluang, investors hold Hilton Hotels Corporation Common Stock for 138 Days and BIO-TECHNE Corp for 63 Days on average.
| HLT | TECH | |
|---|---|---|
Market Cap | $72.14B | $11.37B |
Volume | 862,817 | 3,153,511 |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $72.61 |
52-Week Low | $256.96 | $43.31 |
Typical Hold Time | 138 Days | 63 Days |
Enterprise Value | $85.15B | $11.40B |
Dividend Yield | 0.19% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $320.50, down 0.65% on the day, with strong technical momentum showing a bullish moving average signal. The company demonstrates consistent revenue growth, reaching $12.04 billion in 2025, with earnings beating expectations for three consecutive quarters. Analyst sentiment remains overwhelmingly positive with 57% buy ratings and a $348.11 consensus price target representing 8.6% upside potential. Recent institutional buying activity and upcoming Q3 2026 earnings on October 27 provide near-term catalysts.
Hilton presents a compelling investment case with robust fundamentals and positive momentum, though elevated valuation metrics (P/E of 47.07) and increasing debt levels warrant caution. The stock's technical positioning near key support at $318 suggests potential for continued upward movement if earnings momentum persists, while institutional accumulation and strong travel demand support the bullish thesis.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
